{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:20:53Z","timestamp":1776943253821,"version":"3.51.4"},"reference-count":101,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04423\/2020, UIDP\/04423\/2020, PTDC\/SAU-PUB\/28736\/2017 (reference POCI-01-0145-FEDER-028736)"],"award-info":[{"award-number":["UIDB\/04423\/2020, UIDP\/04423\/2020, PTDC\/SAU-PUB\/28736\/2017 (reference POCI-01-0145-FEDER-028736)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Boron containing compounds have not been widely studied in Medicinal Chemistry, mainly due to the idea that this group could confer some toxicity. Nowadays, this concept has been demystified and, especially after the discovery of the drug bortezomib, the interest for these compounds, mainly boronic acids, has been growing. In this review, several activities of boronic acids, such as anticancer, antibacterial, antiviral activity, and even their application as sensors and delivery systems are addressed. The synthetic processes used to obtain these active compounds are also referred. Noteworthy, the molecular modification by the introduction of boronic acid group to bioactive molecules has shown to modify selectivity, physicochemical, and pharmacokinetic characteristics, with the improvement of the already existing activities. Besides, the preparation of compounds with this chemical group is relatively simple and well known. Taking into consideration these findings, this review reinforces the relevance of extending the studies with boronic acids in Medicinal Chemistry, in order to obtain new promising drugs shortly.<\/jats:p>","DOI":"10.3390\/molecules25184323","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T08:18:01Z","timestamp":1600676281000},"page":"4323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Boronic Acids and Their Derivatives in Medicinal Chemistry: Synthesis and Biological Applications"],"prefix":"10.3390","volume":"25","author":[{"given":"Mariana Pereira","family":"Silva","sequence":"first","affiliation":[{"name":"CIIMAR, Laborat\u00f3rio de Qu\u00edmica Org\u00e2nica e Farmac\u00eautica, Departamento de Ci\u00eancias Qu\u00edmicas, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n\u00b0 228, 4050-313 Porto, Portugal"},{"name":"LAQV\/REQUIMTE, Laborat\u00f3rio de Microbiologia, Departamento de Ci\u00eancias Biol\u00f3gicas, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n\u00b0 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-4939","authenticated-orcid":false,"given":"Luc\u00edlia","family":"Saraiva","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Laborat\u00f3rio de Microbiologia, Departamento de Ci\u00eancias Biol\u00f3gicas, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n\u00b0 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-1409","authenticated-orcid":false,"given":"Madalena","family":"Pinto","sequence":"additional","affiliation":[{"name":"CIIMAR, Laborat\u00f3rio de Qu\u00edmica Org\u00e2nica e Farmac\u00eautica, Departamento de Ci\u00eancias Qu\u00edmicas, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n\u00b0 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-4672","authenticated-orcid":false,"given":"Maria Em\u00edlia","family":"Sousa","sequence":"additional","affiliation":[{"name":"CIIMAR, Laborat\u00f3rio de Qu\u00edmica Org\u00e2nica e Farmac\u00eautica, Departamento de Ci\u00eancias Qu\u00edmicas, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n\u00b0 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ejmech.2019.06.092","article-title":"Boron in drug design: Recent advances in the development of new therapeutic agents","volume":"179","author":"Fernandes","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.4155\/fmc.09.71","article-title":"Therapeutic potential of boron-containing compounds","volume":"1","author":"Baker","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jlac.18601150324","article-title":"Vorl\u00e4ufige Notiz \u00fcber Bor\u00e4thyl","volume":"115","author":"Frankland","year":"1860","journal-title":"Justus Liebigs Ann. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/med.10043","article-title":"Boronic Acid Compounds as Potential Pharmaceutical Agents","volume":"23","author":"Yang","year":"2003","journal-title":"Med. Res. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hall, D.G. (2005). Structure, Properties, and Preparation of Boronic Acid Derivatives. Overview of Their Reactions and Applications. Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine, Wiley-VCH.","DOI":"10.1002\/3527606548.ch1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1016\/j.polymer.2011.07.057","article-title":"Biomedical Applications of Boronic Acid Polymers","volume":"52","author":"Cambre","year":"2011","journal-title":"Polymer (Guildf)"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1039\/c0md00119h","article-title":"Boronic Acids in Medicinal Chemistry: Anticancer, Antibacterial and Antiviral Applications","volume":"1","author":"Trippier","year":"2010","journal-title":"Medchemcomm"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1071\/CH07360","article-title":"Expanding Roles for Organoboron Compounds Versatile and Valuable Molecules for Synthetic, Biological and Medicinal Chemistry","volume":"60","author":"Petasis","year":"2007","journal-title":"Aust. J. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bmc.2004.12.042","article-title":"Structure\u2013activity Relationship for Aryl and Heteroaryl Boronic Acid Inhibitors of Hormone-Sensitive Lipase","volume":"13","author":"Ebdrup","year":"2005","journal-title":"Bioorganic Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/acs.chemrev.5b00300","article-title":"Synthesis and Applications of Boronic Acid-Containing Polymers: From Materials to Medicine","volume":"116","author":"Brooks","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_11","unstructured":"(2020, March 16). Velcade. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/velcade."},{"key":"ref_12","unstructured":"(2020, March 16). Novel Drug Approvals for 2015, Available online: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2015."},{"key":"ref_13","unstructured":"(2020, March 16). Ninlaro. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ninlaro."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","article-title":"Ixazomib: First Global Approval","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"ref_15","unstructured":"(2020, March 16). 2017 New Drug Therapy Approvals, Available online: https:\/\/www.fda.gov\/media\/110526\/download."},{"key":"ref_16","unstructured":"(2020, March 16). Vaborem. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01935-19","article-title":"Biochemical Activity of Vaborbactam","volume":"64","author":"Tsivkovski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3998\/ark.5550190.0014.104","article-title":"Recent Progress in the Synthesis of Pyridinylboronic Acids and Esters","volume":"2013","author":"Liu","year":"2013","journal-title":"Arkivoc"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1039\/C7MD00552K","article-title":"Synthesis of Biologically Active Boron-Containing Compounds","volume":"9","author":"Yang","year":"2018","journal-title":"Medchemcomm"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/med.20105","article-title":"\u03b1-Amido Boronic Acids: A Synthetic Challenge and Their Properties as Serine Protease Inhibitors","volume":"28","author":"Matteson","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.1016\/j.tet.2010.08.001","article-title":"Recent Progress in the Synthesis of Five-Membered Heterocycle Boronic Acids and Esters","volume":"66","author":"Primas","year":"2010","journal-title":"Tetrahedron"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1021\/cr608202m","article-title":"Boron Containing Compounds as Protease Inhibitors","volume":"112","author":"Smoum","year":"2012","journal-title":"Chem. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/cr00039a007","article-title":"Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds","volume":"95","author":"Miyaura","year":"1995","journal-title":"Chem. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Miyaura, N. (2002). Organoboron Compounds. Cross-Coupling Reactions. Topics in Current Chemistry, Springer.","DOI":"10.1007\/3-540-45313-X"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/S0040-4039(98)00504-8","article-title":"New Aryl\/Heteroaryl C-N Bond Cross-Coupling Reactions via Arylboronic Acid\/Cupric Acetate Arylation","volume":"39","author":"Lam","year":"1998","journal-title":"Tetrahedron Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1021\/cr020007u","article-title":"Rhodium-Catalyzed Carbon-Carbon Bond Forming Reactions of Organometallic Compounds","volume":"103","author":"Fagnou","year":"2003","journal-title":"Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1021\/ja0658719","article-title":"Ambient Temperature Synthesis of High Enantiopurity N-Protected Peptidyl Ketones by Peptidyl Thiol Ester-Boronic Acid Cross-Coupling","volume":"129","author":"Yang","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8678","DOI":"10.1021\/jo301642v","article-title":"Scope of the Two-Step, One-Pot Palladium-Catalyzed Borylation\/Suzuki Cross-Coupling Reaction Utilizing Bis-Boronic Acid","volume":"77","author":"Molander","year":"2012","journal-title":"J. Org. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cber.19090420327","article-title":"Die Wirkung der magnesiumorganischen Verbindungen auf die Bors\u00e4ureester","volume":"42","author":"Khotinsky","year":"1909","journal-title":"Chem. Ber."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3891\/acta.chem.scand.11-1075","article-title":"Plant Growth Regulators. II. Methyl- and Methoxysubstituted Naphthylboronic Acids","volume":"11","author":"Lawesson","year":"1957","journal-title":"Acta Chem. Scand."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1021\/jo025792p","article-title":"An Improved Protocol for the Preparation of 3-Pyridyl- and Some Arylboronic Acids","volume":"67","author":"Li","year":"2002","journal-title":"J. Org. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1021\/jo00128a024","article-title":"Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters","volume":"60","author":"Ishiyama","year":"1995","journal-title":"J. Org. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/ja0173019","article-title":"Mild Iridium-Catalyzed Borylation of Arenes. High Turnover Numbers, Room Temperature Reactions, and Isolation of a Potential Intermediate","volume":"124","author":"Ishiyama","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/1521-3773(20010601)40:11<2168::AID-ANIE2168>3.0.CO;2-0","article-title":"Formation of Aryl- and Benzylboronate Esters by Rhodium-Catalyzed C-H Bond Functionalization with Pinacolborane","volume":"40","author":"Shimada","year":"2001","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1021\/acs.oprd.8b00118","article-title":"Effective Utilization of Flow Chemistry: Use of Unstable Intermediates, Inhibition of Side Reactions, and Scale-Up for Boronic Acid Synthesis","volume":"22","author":"Usutani","year":"2018","journal-title":"Org. Process Res. Dev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/S0040-4039(00)95599-0","article-title":"Synthetic Connections to the Aromatic Directed Metalation Reaction. Functionalized Aryl Boronic Acids by Ipso Borodesilylation. General Syntheses of Unsymmetrical Biphenyls and m-Terphenyls","volume":"28","author":"Sharp","year":"1987","journal-title":"Tetrahedron Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.105.021311","article-title":"A Boronic-Chalcone Derivative Exhibits Potent Anticancer Activity through Inhibition of the Proteasome","volume":"70","author":"Achanta","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","article-title":"ChemInform Abstract: Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids","volume":"8","author":"Adams","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1016\/j.bmc.2016.04.025","article-title":"3D-QSAR-Aided Design, Synthesis, in Vitro and in Vivo Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors and Mechanism Studies","volume":"24","author":"Lei","year":"2016","journal-title":"Bioorganic Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1021\/jm1005012","article-title":"Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin","volume":"53","author":"Albers","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1021\/jm030213+","article-title":"Design, Synthesis, and Evaluation of Novel Boronic-Chalcone Derivatives as Antitumor Agents","volume":"46","author":"Kumar","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 Conceals the Activation Domain of Tumor Suppressor P53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.bmc.2018.06.020","article-title":"Design, synthesis, in vitro and in vivo evaluation, and structure\u2013activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies","volume":"26","author":"Lei","year":"2018","journal-title":"Bioorganic Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ejmech.2016.10.023","article-title":"Urea-Containing Peptide Boronic Acids as Potent Proteasome Inhibitors","volume":"125","author":"Han","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.chembiol.2005.06.016","article-title":"Structure-Based Discovery of a Boronic Acid Bioisostere of Combretastatin A-4","volume":"12","author":"Kong","year":"2005","journal-title":"Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bmc.2009.11.003","article-title":"A Boronic Acid Chalcone Analog of Combretastatin A-4 as a Potent Anti-Proliferation Agent","volume":"18","author":"Kong","year":"2010","journal-title":"Bioorganic Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1021\/acs.jmedchem.6b00753","article-title":"Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)","volume":"59","author":"Liu","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejmech.2016.03.063","article-title":"10-Boronic Acid Substituted Camptothecin as Prodrug of SN-38","volume":"116","author":"Wang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting Cancer Cells by ROS-Mediated Mechanisms: A Radical Therapeutic Approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1021\/ja210719s","article-title":"Boronate-Mediated Biologic Delivery","volume":"134","author":"Ellis","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1021\/acs.jmedchem.7b01775","article-title":"Synthesis and Evaluation of Hydrogen Peroxide Sensitive Prodrugs of Methotrexate and Aminopterin for the Treatment of Rheumatoid Arthritis","volume":"61","author":"Bondebjerg","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bielec, B., Poetsch, I., Ahmed, E., Heffeter, P., Keppler, B.K., and Kowol, C.R. (2020). Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. Molecules, 25.","DOI":"10.3390\/molecules25051149"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1021\/jm200310q","article-title":"Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin","volume":"54","author":"Albers","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1021\/jm900125m","article-title":"Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors","volume":"52","author":"Suzuki","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/acs.jmedchem.9b02161","article-title":"Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma","volume":"63","author":"Zhou","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1021\/acs.jmedchem.5b00341","article-title":"Click Chemistry in Lead Optimization of Boronic Acids as \u03b2-Lactamase Inhibitors","volume":"58","author":"Caselli","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid \u03b2-Lactamase Inhibitor (RPX7009) with Utility vs. Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fmicb.2020.00035","article-title":"The \u03b2-Lactamase Inhibitor Boronic Acid Derivative SM23 as a New Anti-Pseudomonas Aeruginosa Biofilm","volume":"11","author":"Peppoloni","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"126795","DOI":"10.1016\/j.bmcl.2019.126795","article-title":"Serendipitous Discovery of Aryl Boronic Acids as \u03b2-Lactamase Inhibitors","volume":"30","author":"Yang","year":"2020","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/bj1690197","article-title":"Reversible inhibitors of penicillinases","volume":"169","author":"Kiener","year":"1978","journal-title":"Biochem. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1021\/ja0288338","article-title":"Nanomolar Inhibitors of AmpC \u03b2-Lactamase","volume":"125","author":"Morandi","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1021\/acsinfecdis.7b00153","article-title":"Inhibition of Acinetobacter -Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel \u03b2-Lactamase Inhibitors","volume":"4","author":"Caselli","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.1208337109","article-title":"Fragment-Guided Design of Subnanomolar \u03b2-Lactamase Inhibitors Active in Vivo","volume":"109","author":"Eidam","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1021\/acs.jmedchem.9b01976","article-title":"Discovery of Cyclic Boronic Acid QPX7728, an Ultra-Broad-Spectrum Inhibitor of Serine and Metallo Beta-Lactamases","volume":"63","author":"Hecker","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2015.02.056","article-title":"Boronic Species as Promising Inhibitors of the Staphylococcus Aureus NorA Efflux Pump: Study of 6-Substituted Pyridine-3-Boronic Acid Derivatives","volume":"95","author":"Fontaine","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_68","first-page":"6030","article-title":"Medicinal Chemistry Updates on Bacterial Efflux Pump Modulators","volume":"25","author":"Pinto","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.bmcl.2017.03.070","article-title":"Novel Boronic Acid Derivatives of Bis(Indolyl) Methane as Anti-MRSA Agents","volume":"27","author":"Mandal","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1039\/C3CC00243H","article-title":"Branched Peptide Boronic Acids (BPBAs): A Novel Mode of Binding towards RNA","volume":"49","author":"Zhang","year":"2013","journal-title":"Chem. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1016\/j.bmc.2016.04.009","article-title":"Characterization and in Vitro Activity of a Branched Peptide Boronic Acid That Interacts with HIV-1 RRE RNA","volume":"24","author":"Wynn","year":"2016","journal-title":"Bioorganic Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"14015","DOI":"10.1021\/jacs.8b07366","article-title":"Sub-Picomolar Inhibition of HIV-1 Protease with a Boronic Acid","volume":"140","author":"Windsor","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/cmdc.201900508","article-title":"Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1021\/acs.jmedchem.6b00326","article-title":"Boronic Acid Modifications Enhance the Anti-Influenza A Virus Activities of Novel Quindoline Derivatives","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1568005043340920","article-title":"Antiviral Properties of Quinolone-Based Drugs","volume":"4","author":"Richter","year":"2004","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1021\/jm400317w","article-title":"Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase","volume":"57","author":"Maynard","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cpdd.142","article-title":"A Randomized, Double Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects","volume":"3","author":"Wilfret","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/acs.jmedchem.8b01719","article-title":"Design of N-Benzoxaborole Benzofuran GSK8175\u2014Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor","volume":"62","author":"Chong","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1021\/acs.jmedchem.6b01021","article-title":"Peptide-Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology","volume":"60","author":"Nitsche","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1039\/C9AN00741E","article-title":"Boronic Acid Sensors with Double Recognition Sites: A Review","volume":"145","author":"Bian","year":"2020","journal-title":"Analyst"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-42812-8","article-title":"Boronic Acid Appended Naphthyl-Pyridinium Receptors as Chemosensors for Sugars","volume":"9","author":"Resendez","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_82","first-page":"377","article-title":"Antibacterial borazaro derivatives. I. 5-Arylsulphonyl-4-hydroxy-4,5-borazarothieno(2,3-c)pyridines and 6-arylsulphonyl-7-hydroxy-7,6-borazarothieno(3,2-c)pyridines","volume":"8","author":"Gronowitz","year":"1971","journal-title":"Acta Pharm. Suec."},{"key":"ref_83","first-page":"623","article-title":"Antibacterial borazaro derivatives. II. Effect of substituents on the antibacterial activity of 5-arylsulfonyl-4hydroxy-4,5-borazarothieno(2,3-c)pyridines and 6-arylsulfonyl-7-hydroxy-7,6- borazarothieno(3,2-c)pyridines","volume":"8","author":"Gronowitz","year":"1971","journal-title":"Acta Pharm. Suec."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/jm00374a003","article-title":"Preparation and Antibacterial Activities of New 1, 2, 3-Diazaborine Derivatives and Analogues","volume":"27","author":"Grassberger","year":"1984","journal-title":"J. Med. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00045391-200109000-00005","article-title":"Boron Therapeutics on the Horizon","volume":"8","author":"Groziak","year":"2001","journal-title":"Am. J. Ther."},{"key":"ref_86","first-page":"507","article-title":"Arylboronic acids. III. Bromination of tolylboronic acids according to WohlZiegler","volume":"10","author":"Torssell","year":"1957","journal-title":"Ark. Kemi."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/13543776.2018.1473379","article-title":"Benzoxaborole compounds for therapeutic uses: A patent review (2010\u20132018)","volume":"28","author":"Nocentini","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/0976-500X.171870","article-title":"An upcoming drug for onychomycosis: Tavaborole","volume":"6","author":"Sharma","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.jorganchem.2009.07.022","article-title":"Benzoxaboroles\u2014Old compounds with new applications","volume":"694","author":"Cyranski","year":"2009","journal-title":"J. Organomet. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.1142189","article-title":"An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site","volume":"316","author":"Rock","year":"2007","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a Potent and Specific, M. Tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-Chloro-7-(2-Hydroxyethoxy)Benzo[c][1,2]Oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1198311986","DOI":"10.1039\/C6CC06399C","article-title":"Benzoxaborole as a new chemotype for carbonic anhydrase inhibition","volume":"52","author":"Alterio","year":"2016","journal-title":"Chem. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11941198","DOI":"10.1021\/acsmedchemlett.7b00369","article-title":"Benzoxaboroles as efficient inhibitors of the \u03b2-carbonic anhydrases from pathogenic fungi: Activity and modeling study","volume":"8","author":"Nocentini","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1021\/acs.jmedchem.7b00621","article-title":"Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate","volume":"60","author":"Zhang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.bmcl.2016.04.093","article-title":"Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide","volume":"26","author":"Zhang","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e02419-17","DOI":"10.1128\/AAC.02419-17","article-title":"Topical treatment for cutaneous Leishmaniasis: Dermato-pharmacokinetic lead optimization of benzoxaboroles","volume":"62","author":"Gaukel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1021\/acsinfecdis.5b00031","article-title":"4,5-Disubstituted 6-Aryloxy-1,3dihydrobenzo[c][1,2]oxaboroles are broad-spectrum serine \u03b2-lactamase inhibitors","volume":"1","author":"McKinney","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10637-018-0611-z","article-title":"Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology e phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells","volume":"37","author":"Psurski","year":"2019","journal-title":"Investig. New Drugs."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2019.06.1288","article-title":"Crisaborole 2% Ointment for the Treatment of Intertriginous, Anogenital, and Facial Psoriasis: A DoubleBlind, Randomized, Vehicle-Controlled Trial","volume":"82","author":"Hashim","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1021\/jm500045x","article-title":"Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates","volume":"57","author":"Kawamura","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.ejmech.2018.08.086","article-title":"Boronic Ester-Linked Macrocyclic Lipopeptides as Serine Protease Inhibitors Targeting Escherichia Coli Type I Signal Peptidase","volume":"157","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/18\/4323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:11:59Z","timestamp":1760177519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/18\/4323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":101,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["molecules25184323"],"URL":"https:\/\/doi.org\/10.3390\/molecules25184323","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}